about
Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapyInfluenza A (H1N1) in a pediatric patient with newly diagnosed acute promyelocytic leukemia and invasive pulmonary aspergillosis.Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP).Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience.Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.Growth impairment after TBI of leukemia survivors children: a model- based investigation.Ewing sarcoma of the bone in children under 6 years of ageLate effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum.Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis.Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study.Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of boneValidation of analytical methods in GMP: the disposable Fast Read 102® device, an alternative practical approach for cell counting.Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registryValidation of analytical methods in compliance with good manufacturing practice: a practical approachFunctional evaluation of circulating hematopoietic progenitors in Noonan syndromePoor prognosis osteosarcoma: new therapeutic approach.Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bedInnovative approaches to treat steroid-resistant or steroid refractory GVHD.Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment.ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.Stem cells in amyotrophic lateral sclerosis: state of the art.Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.Transplantation of mesenchymal stem cells in ALS.Ovarian tissue cryopreservation in girls undergoing haematopoietic stem cell transplant: experience of a single centre.Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors.Tumor-associated-antigens or osteosarcoma cell line lysates: two efficient methods for in vitro generation of CTLs with special regard to MHC-I restriction.Adolescents with Cancer in Italy: Improving Access to National Cooperative Pediatric Oncology Group (AIEOP) Centers.Interactions between osteosarcoma cell lines and dendritic cells immune function: An in vitro study.Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta.Incidence of colonization and bloodstream infection with carbapenem-resistant Enterobacteriaceae in children receiving antineoplastic chemotherapy in Italy.Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.Development of a Low-Cost Stem-Loop Real-Time Quantification PCR Technique for EBV miRNA Expression Analysis.CMV induces HERV-K and HERV-W expression in kidney transplant recipients.Gonadal status in long-term male survivors of childhood cancer.
P50
Q26825272-16EA1B93-52E7-482A-B70B-39CF8C42C6E8Q30407382-7010166F-FBB6-4D06-859E-6E30366B89F7Q33366193-D34E1A83-8CE9-4E44-9DC5-FEA90770BAE2Q33410703-BC8533CC-B8AF-4402-9155-9FC06383FCF8Q33411730-1E5AE326-118A-4A63-99C7-300B73DF8632Q33419286-9A973839-F448-449D-88ED-0F492F2790C1Q33582914-301D68E4-1E25-4C2F-B22D-5042619221D9Q34422867-D9612E3D-46EA-4876-93AC-101945E3C1E4Q34575191-D524CAB2-EDD4-437A-B63E-5993FDF58F11Q34636631-105A8D11-B9FC-4300-AFD9-DDFF88860D5CQ34638074-8D1F79CF-B98A-4EDF-979A-995A2DE6DBEAQ35073287-E2674E72-6000-4213-9CCB-4148B3A8BCD6Q35200293-F554D898-B933-400E-9BDF-B76A1DB0ADD9Q35495340-42E4F007-83D8-49BE-8340-81F2FBB9F4B9Q35995283-1D1A70EC-0FA0-43B3-B14E-D8A4AF91B0DAQ36411999-F12532A9-2A83-41E3-8ECA-82DE2EED9D53Q36425742-DBFB0AD1-5C16-4FB4-980E-072362E46079Q37152649-2714FEBD-4176-4565-81A3-0B0547CB4B50Q37181699-5C875764-096A-4C96-ACA5-F58026550D86Q37188469-CA0BDB88-F176-4FEA-8E7A-36074B803571Q37273398-6103E077-AC4B-4471-A377-87D71442801DQ37315358-F87C9E74-16C9-410F-85C1-686A7CC8C36FQ37323038-9C59433B-1B12-4760-907B-3DC170506F1AQ37355020-C1A861AA-6D71-448C-87EB-B3E92ED2A2A1Q37575591-8F01780E-8CC0-4A79-BCA4-FF250DC37FA3Q38002494-EE60C851-59FB-48AB-A97F-528C05B3BBF2Q38063000-3D369C1B-AB03-41EC-B4F1-A54276DAABC7Q39008643-1DBF1BD3-87C1-4F2F-B0AC-00BD7FEB225DQ39041744-C15AF285-42D0-4DD3-843C-7E49641F9472Q39389679-D4353E2C-7FCE-456F-8383-E9FA1E8BD240Q39637336-CB557414-DF14-4948-8725-0F4EBDDCC657Q39969220-37F96543-06C5-44BD-93C2-448FE79DA7E9Q39970655-6CC42D44-D292-4DAE-8561-FEBAEF78D04AQ40029636-B6BA7DBE-BA09-467F-94D8-5F3CE592D899Q40311807-1BA3B471-5558-4C85-AEEF-33FDB3B47C7DQ40515306-B3DFAA95-C8C9-472A-8F4B-6F4B6E166D11Q40681571-929BB1EF-8560-4D47-ABC7-F4EB64C01FCBQ40726075-6324AC9B-745D-42B2-B36C-FDBCAC906A87Q40839118-7112035B-AB30-4B67-B837-15183C2F1560Q40919926-5F9D4B65-9C79-483F-A375-DD3B51BD9287
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Franca Fagioli
@ast
Franca Fagioli
@en
Franca Fagioli
@es
Franca Fagioli
@nl
type
label
Franca Fagioli
@ast
Franca Fagioli
@en
Franca Fagioli
@es
Franca Fagioli
@nl
prefLabel
Franca Fagioli
@ast
Franca Fagioli
@en
Franca Fagioli
@es
Franca Fagioli
@nl
P106
P1153
7005370572
P31
P496
0000-0002-9257-900X